Navigation Links
The CementBloc and Novartis Vaccines to Jointly Present Top Considerations in Interactive Selling at the 11th Annual iPharmaConnect
Date:3/21/2012

NEW YORK, March 21, 2012 /PRNewswire/ -- Meghan Lopresto, VP, Sales Force Automation Analytics at The CementBloc, and Emad Abdelnaby, Director of Marketing at Novartis Vaccines, will be co-presenting their expertise in interactive selling at CBI's iPharmaConnect plenary session on March 27, 2012, in Philadelphia.

The conference is a 3-day symposium that will unite senior-level marketing, digital, brand, and medical affairs professionals to discuss novel approaches to thriving multichannel digital campaigns. From the client and agency perspectives, Ms. Lopresto and Mr. Abdelnaby will be presenting the success story behind the recently rolled-out program at Novartis Vaccines. Their talk, entitled, "Develop a Road Map for Transforming Your Organization Through Interactive Selling" will serve as an essential blueprint for optimizing iPad selling across an organization. 

"Transitioning your field sales team over to an iPad platform is more than just an upgrade of their technology," says Ms. Lopresto. "It represents a key shift in the engagement between sales representatives and their customers. A successful rollout of these new tools requires a defined road map of the process, including agreed-upon core principles and buy-in from multiple stakeholders. If this is achieved, an organization can be transformed, for the better, through interactive selling."

At The CementBloc, Ms. Lopresto plays a key role in interactive selling tool development and measurement, multichannel marketing planning and analytics, promotional spend optimization, CRM/PRM, and closed-loop marketing initiatives. For more than 10 years, Meghan has been in the pharmaceutical industry in leadership roles, providing clients with innovative solutions for multichannel and professional advertising campaigns. 

As Director of Marketing for the US Meningococcal Franchise at Novartis Vaccines and Diagnostics (NVD), Mr. Abdelnaby has responsibility for the development
'/>"/>

SOURCE The CementBloc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ira Haimowitz, PhD, EVP, Group Director, Intelligence and Analytics at The CementBloc, to Present at Aberdeen Group Inaugural Business Analytics Summit
2. Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
9. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
10. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
11. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... REGN ) today announced results from the Phase ... Trap) for the second-line treatment of non-small cell lung ... the chemotherapy drug docetaxel did not meet the pre-specified ...
... Nephros, Inc. (OTC Bulletin Board: NEPH ), ... for therapeutic applications, infection control, and water purification, today ... placement that together resulted in gross proceeds of approximately ... by Nephros from the rights offering and private placement ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 2Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 3Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 4
(Date:7/11/2014)... Datalogic brings a new and innovative scanner ... With their new Gryphon GD4400 and GM4400 ... devastating MRSA, which claimed 5,500 lives, becomes more preventable. ... and the Gryphon GM4400-HC 2D readers can scan nearly ... barcodes off of troublesome LCD monitors, smartphones, and other ...
(Date:7/11/2014)... Boston, MA (PRWEB) July 11, 2014 ... save at least $50 billion in fuel ... effect immediately. The current GHG standards ... manufacturers have taken it upon themselves to ... they include: , 1.    Idle reduction technologies , ...
(Date:7/11/2014)... (HealthDay News) -- Children who have emergency surgery ... and potentially even death than those who have ... However, the Johns Hopkins researchers noted that the ... analyzed data on nearly 440,000 simple emergency surgeries ... a 22-year period. The surgeries are considered ...
(Date:7/11/2014)... Oakland, CA (PRWEB) July 11, 2014 Ticket ... tickets at the Concord Pavilion . When it comes to ... from Luke Bryan. The 37-year-old Georgia native is one of the ... in the entertainment business. Bryan is currently out on his “That’s ... Among the many stops the tour will be making through the ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, ... exclusively to cell and gene therapies for cancer ... the organization as Senior Development Officer. , Corday ... securing gifts and addressing influential donors. Prior to ... for NewYork Presbyterian Hospital/Columbia University Medical Center, where ...
Breaking Medicine News(10 mins):Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... -- The rising prevalence of obesity around the globe ... on healthcare systems and on overall economies. A major ... these burdens to inform public policies. Using a ... consequences from rising obesity rates in the United States ...
... , FRIDAY, Aug. 26 (HealthDay News) -- Scientists ... most common noncancerous tumors in women of childbearing age. ... discomfort, occur in 60 percent of women by the age ... the most common reason for hysterectomy. Despite their importance, ...
... THURSDAY, Aug. 25 (HealthDay News) -- A new scoring system might ... how much time they have left so they can prepare for ... in Palliative Care Study (PiPS) predictor model, the scoring system plugs ... or months a person with advanced cancer most likely has to ...
... People with lower socioeconomic status are much more likely to ... educated, according to a recent UC Davis study. Published online ... that this risk persists even with long-term progress in addressing ... elevated cholesterol. "Being poor or having less than ...
... , THURSDAY, Aug. 25 (HealthDay News) -- One of the ... was the secrecy that shrouded products he was about to ... iPad -- creating tremendous consumer interest. Jobs, announcement Wednesday ... the hugely successful technology company he co-founded in a northern ...
... News) -- The number of obese people in the United States ... 2030, and the number of obese people in the United Kingdom ... predicts. Obesity-related diseases and health care costs will soar as ... The Lancet . Already, the U.S. and U.K. obesity rates ...
Cached Medicine News:Health News:65 million more obese adults in the US and 11 million more in the UK expected by 2030 2Health News:65 million more obese adults in the US and 11 million more in the UK expected by 2030 3Health News:Scoring System May Tell the Dying How Long They Have to Live 2Health News:Lower socioeconomic status linked with heart disease despite improvements in other risk factor 2Health News:Steve Jobs Faces Uphill Battle Against Cancer: Experts 2Health News:Steve Jobs Faces Uphill Battle Against Cancer: Experts 3Health News:Obesity Continues to Balloon in U.S. and U.K.: Study 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: